Cleveland Clinic lists biomarker for Alzheimer's as top medical innovation
A new PET biomarker for early detection of Alzheimer's disease called AV-45 has been listed by the Cleveland Clinic as the top emerging medical innovation for 2011.
Currently, positive diagnosis of Alzheimer's is only possible upon autopsy. But PET imaging using a radioactive molecular imaging compound called AV-45 can allow doctors to detect beta-amyloid plaques, the tell-tale signature of Alzheimer's.
A panel of Cleveland Clinic physicians and scientists selected the top 10 devices and therapies, and unveiled them during the provider’s 2010 Medical Innovation Summit.
The Top 10 Medical Innovations had to meet four major criteria for qualification and selection, which included:
Currently, positive diagnosis of Alzheimer's is only possible upon autopsy. But PET imaging using a radioactive molecular imaging compound called AV-45 can allow doctors to detect beta-amyloid plaques, the tell-tale signature of Alzheimer's.
A panel of Cleveland Clinic physicians and scientists selected the top 10 devices and therapies, and unveiled them during the provider’s 2010 Medical Innovation Summit.
The Top 10 Medical Innovations had to meet four major criteria for qualification and selection, which included:
- Significant potential for short-term clinical impact (either a major improvement in patient benefit or an improved function that enhances healthcare delivery);
- High probability of success;
- On the market or close to being introduced; and
- Sufficient data available to support its nomination.